Cribriform versus Intraductal: How to Determine the Difference
Abstract
:Simple Summary
Abstract
1. Introduction
2. Intraductal Carcinoma of the Prostate
3. Cribriform Prostate Cancer
4. Differential Diagnoses
5. Current Recommendations for IDC-P and cPCa
6. Conclusions and Outlook
Author Contributions
Funding
Conflicts of Interest
References
- Epstein, J.I.; Amin, M.B.; Fine, S.W.; Algaba, F.; Aron, M.; Baydar, D.E.; Beltran, A.L.; Brimo, F.; Cheville, J.C.; Colecchia, M.; et al. The 2019 Genitourinary Pathology Society (GUPS) White Paper on Contemporary Grading of Prostate Cancer. Arch. Pathol. Lab. Med. 2021, 145, 461–493. [Google Scholar] [CrossRef] [PubMed]
- Rhamy, R.K.; Buchanan, R.D.; Spalding, M.J. Intraductal carcinoma of the prostate gland. Trans. Am. Assoc. Genitourin. Surg. 1972, 64, 61–68. [Google Scholar] [CrossRef] [PubMed]
- Kovi, J.; Jackson, M.A.; Heshmat, M.Y. Ductal spread in prostatic carcinoma. Cancer 1985, 56, 1566–1573. [Google Scholar] [CrossRef] [PubMed]
- WHO Classification of Tumours Editorial Board. Urinary and male genital tumours. In WHO Classification of Tumours Series, 5th ed.; International Agency for Research on Cancer: Lyon, France, 2022; Volume 8, Available online: https://publications.iarc.fr (accessed on 1 March 2024).
- Miyai, K.; Divatia, M.K.; Shen, S.S.; Miles, B.J.; Ayala, A.G.; Ro, J.Y. Heterogeneous clinicopathological features of intraductal carcinoma of the prostate: A comparison between “precursor-like” and “regular type” lesions. Int. J. Clin. Exp. Pathol. 2014, 7, 2518–2526. [Google Scholar] [PubMed]
- Robinson, B.D.; Epstein, J.I. Intraductal carcinoma of the prostate without invasive carcinoma on needle biopsy: Emphasis on radical prostatectomy findings. J. Urol. 2010, 184, 1328–1333. [Google Scholar] [CrossRef]
- Guo, C.C.; Epstein, J.I. Intraductal carcinoma of the prostate on needle biopsy: Histologic features and clinical significance. Mod. Pathol. 2006, 19, 1528–1535. [Google Scholar] [CrossRef] [PubMed]
- McNeal, J.E.; Yemoto, C.E. Spread of adenocarcinoma within prostatic ducts and acini. Morphologic and clinical correlations. Am. J. Surg. Pathol. 1996, 20, 802–814. [Google Scholar] [CrossRef]
- Cohen, R.J.; Chan, W.C.; Edgar, S.G.; Robinson, E.; Dodd, N.; Hoscek, S.; Mundy, I.P. Prediction of pathological stage and clinical outcome in prostate cancer: An improved pre-operative model incorporating biopsy-determined intraductal carcinoma. Br. J. Urol. 1998, 81, 413–418. [Google Scholar] [CrossRef] [PubMed]
- Fine, S.W.; Al-Ahmadie, H.A.; Chen, Y.-B.; Gopalan, A.; Tickoo, S.K.; Reuter, V.E. Comedonecrosis Revisited: Strong Association with Intraductal Carcinoma of the Prostate. Am. J. Surg. Pathol. 2018, 42, 1036–1041. [Google Scholar] [CrossRef]
- Madan, R.; Deebajah, M.; Alanee, S.; Gupta, N.S.; Carskadon, S.; Palanisamy, N.; Williamson, S.R. Prostate cancer with comedonecrosis is frequently, but not exclusively, intraductal carcinoma: A need for reappraisal of grading criteria. Histopathology 2019, 74, 1081–1087. [Google Scholar] [CrossRef]
- Lam, T.B.L.; MacLennan, S.; Willemse, P.-P.M.; Mason, M.D.; Plass, K.; Shepherd, R.; Baanders, R.; Bangma, C.H.; Bjartell, A.; Bossi, A.; et al. EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study). Eur. Urol. 2019, 76, 790–813. [Google Scholar] [CrossRef] [PubMed]
- Dinerman, B.F.; Khani, F.; Golan, R.; Bernstein, A.N.; Cosiano, M.F.; Margolis, D.J.; Hu, J.C. Population-based study of the incidence and survival for intraductal carcinoma of the prostate. Urol. Oncol. 2017, 35, e9–e673. [Google Scholar] [CrossRef] [PubMed]
- Efstathiou, E.; Abrahams, N.A.; Tibbs, R.F.; Wang, X.; Pettaway, C.A.; Pisters, L.L.; Mathew, P.F.; Do, K.-A.; Logothetis, C.J.; Troncoso, P. Morphologic characterization of preoperatively treated prostate cancer: Toward a post-therapy histologic classification. Eur. Urol. 2010, 57, 1030–1038. [Google Scholar] [CrossRef] [PubMed]
- Kimura, K.; Tsuzuki, T.; Kato, M.; Saito, A.M.; Sassa, N.; Ishida, R.; Hirabayashi, H.; Yoshino, Y.; Hattori, R.; Gotoh, M. Prognostic value of intraductal carcinoma of the prostate in radical prostatectomy specimens. Prostate 2014, 74, 680–687. [Google Scholar] [CrossRef] [PubMed]
- Miyai, K.; Divatia, M.K.; Shen, S.S.; Miles, B.J.; Ayala, A.G.; Ro, J.Y. Clinicopathological analysis of intraductal proliferative lesions of prostate: Intraductal carcinoma of prostate, high-grade prostatic intraepithelial neoplasia, and atypical cribriform lesion. Human. Pathol. 2014, 45, 1572–1581. [Google Scholar] [CrossRef] [PubMed]
- O’Brien, C.; True, L.D.; Higano, C.S.; Rademacher, B.L.S.; Garzotto, M.; Beer, T.M. Histologic changes associated with neoadjuvant chemotherapy are predictive of nodal metastases in patients with high-risk prostate cancer. Am. J. Clin. Pathol. 2010, 133, 654–661. [Google Scholar] [CrossRef] [PubMed]
- Yamamoto, A.; Kato, M.; Matsui, H.; Ishida, R.; Kimura, T.; Funahashi, Y.; Sassa, N.; Matsukawa, Y.; Kamihira, O.; Hattori, R.; et al. Efficacy of docetaxel in castration-resistant prostate cancer patients with intraductal carcinoma of the prostate. Int. J. Clin. Oncol. 2018, 23, 584–590. [Google Scholar] [CrossRef]
- Porter, L.H.; Lawrence, M.G.; Ilic, D.; Clouston, D.; Bolton, D.M.; Frydenberg, M.; Murphy, D.G.; Pezaro, C.; Risbridger, G.P.; Taylor, R.A. Systematic Review Links the Prevalence of Intraductal Carcinoma of the Prostate to Prostate Cancer Risk Categories. Eur. Urol. 2017, 72, 492–495. [Google Scholar] [CrossRef]
- Kato, M.; Hirakawa, A.; Kobayashi, Y.; Yamamoto, A.; Ishida, R.; Kamihira, O.; Kimura, T.; Majima, T.; Ishida, S.; Funahashi, Y.; et al. Integrating tertiary Gleason pattern 5 into the ISUP grading system improves prediction of biochemical recurrence in radical prostatectomy patients. Mod. Pathol. 2019, 32, 122–127. [Google Scholar] [CrossRef]
- Saeter, T.; Vlatkovic, L.; Waaler, G.; Servoll, E.; Nesland, J.M.; Axcrona, K.; Axcrona, U. Intraductal Carcinoma of the Prostate on Diagnostic Needle Biopsy Predicts Prostate Cancer Mortality: A Population-Based Study. Prostate 2017, 77, 859–865. [Google Scholar] [CrossRef]
- Trinh, V.Q.; Sirois, J.; Benzerdjeb, N.; Mansoori, B.K.; Grosset, A.-A.; Albadine, R.; Latour, M.; Mes-Masson, A.-M.; Hovington, H.; Bergeron, A.; et al. The impact of intraductal carcinoma of the prostate on the site and timing of recurrence and cancer-specific survival. Prostate 2018, 78, 697–706. [Google Scholar] [CrossRef] [PubMed]
- Van der Kwast, T.; Al Daoud, N.; Collette, L.; Sykes, J.; Thoms, J.; Milosevic, M.; Bristow, R.G.; Van Tienhoven, G.; Warde, P.; Mirimanoff, R.-O.; et al. Biopsy diagnosis of intraductal carcinoma is prognostic in intermediate and high risk prostate cancer patients treated by radiotherapy. Eur. J. Cancer 2012, 48, 1318–1325. [Google Scholar] [CrossRef] [PubMed]
- Böttcher, R.; Kweldam, C.F.; Livingstone, J.; Lalonde, E.; Yamaguchi, T.N.; Huang, V.; Yousif, F.; Fraser, M.; Bristow, R.G.; van der Kwast, T.; et al. Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations. BMC Cancer 2018, 18, 8. [Google Scholar] [CrossRef] [PubMed]
- Risbridger, G.P.; Taylor, R.A.; Clouston, D.; Sliwinski, A.; Thorne, H.; Hunter, S.; Li, J.; Mitchell, G.; Murphy, D.; Frydenberg, M.; et al. Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis. Eur. Urol. 2015, 67, 496–503. [Google Scholar] [CrossRef] [PubMed]
- Isaacsson Velho, P.; Silberstein, J.L.; Markowski, M.C.; Luo, J.; Lotan, T.L.; Isaacs, W.B.; Antonarakis, E.S. Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer. Prostate 2018, 78, 401–407. [Google Scholar] [CrossRef] [PubMed]
- Giri, V.N.; Knudsen, K.E.; Kelly, W.K.; Cheng, H.H.; Cooney, K.A.; Cookson, M.S.; Dahut, W.; Weissman, S.; Soule, H.R.; Petrylak, D.P.; et al. Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. J. Clin. Oncol. 2020, 38, 2798–2811. [Google Scholar] [CrossRef] [PubMed]
- Lozano, R.; Salles, D.C.; Sandhu, S.; Aragón, I.M.; Thorne, H.; López-Campos, F.; Rubio-Briones, J.; Gutierrez-Pecharroman, A.M.; Maldonado, L.; di Domenico, T.; et al. Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancer. Eur. J. Cancer 2021, 147, 74–83. [Google Scholar] [CrossRef] [PubMed]
- Bernhardt, M.; Kristiansen, G. Molecular Alterations in Intraductal Carcinoma of the Prostate. Cancers 2023, 15, 5512. [Google Scholar] [CrossRef] [PubMed]
- Montironi, R.; Cimadamore, A.; Gasparrini, S.; Mazzucchelli, R.; Santoni, M.; Massari, F.; Cheng, L.; Lopez-Beltran, A.; Scarpelli, M. Prostate cancer with cribriform morphology: Diagnosis, aggressiveness, molecular pathology and possible relationships with intraductal carcinoma. Expert. Rev. Anticancer. Ther. 2018, 18, 685–693. [Google Scholar] [CrossRef]
- Kweldam, C.F.; Kümmerlin, I.P.; Nieboer, D.; Verhoef, E.I.; Steyerberg, E.W.; van der Kwast, T.H.; Roobol, M.J.; van Leenders, G.J. Disease-specific survival of patients with invasive cribriform and intraductal prostate cancer at diagnostic biopsy. Mod. Pathol. 2016, 29, 630–636. [Google Scholar] [CrossRef]
- Hollemans, E.; Verhoef, E.I.; Bangma, C.H.; Schoots, I.; Rietbergen, J.; Helleman, J.; Roobol, M.J.; van Leenders, G.J.L.H. Concordance of cribriform architecture in matched prostate cancer biopsy and radical prostatectomy specimens. Histopathology 2019, 75, 338–345. [Google Scholar] [CrossRef]
- Trudel, D.; Downes, M.R.; Sykes, J.; Kron, K.J.; Trachtenberg, J.; van der Kwast, T.H. Prognostic impact of intraductal carcinoma and large cribriform carcinoma architecture after prostatectomy in a contemporary cohort. Eur. J. Cancer 2014, 50, 1610–1616. [Google Scholar] [CrossRef]
- Choy, B.; Pearce, S.M.; Anderson, B.B.; Shalhav, A.L.; Zagaja, G.; Eggener, S.E.; Paner, G.P. Prognostic Significance of Percentage and Architectural Types of Contemporary Gleason Pattern 4 Prostate Cancer in Radical Prostatectomy. Am. J. Surg. Pathol. 2016, 40, 1400–1406. [Google Scholar] [CrossRef]
- Iczkowski, K.A.; Torkko, K.C.; Kotnis, G.R.; Wilson, R.S.; Huang, W.; Wheeler, T.M.; Abeyta, A.M.; La Rosa, F.G.; Cook, S.; Werahera, P.N.; et al. Digital quantification of five high-grade prostate cancer patterns, including the cribriform pattern, and their association with adverse outcome. Am. J. Clin. Pathol. 2011, 136, 98–107. [Google Scholar] [CrossRef] [PubMed]
- Hollemans, E.; Verhoef, E.I.; Bangma, C.H.; Rietbergen, J.; Helleman, J.; Roobol, M.J.; van Leenders, G.J.L.H. Large cribriform growth pattern identifies ISUP grade 2 prostate cancer at high risk for recurrence and metastasis. Mod. Pathol. 2019, 32, 139–146. [Google Scholar] [CrossRef]
- Dong, F.; Wang, C.; Farris, A.B.; Wu, S.; Lee, H.; Olumi, A.F.; McDougal, W.S.; Young, R.H.; Wu, C.-L. Impact on the clinical outcome of prostate cancer by the 2005 international society of urological pathology modified Gleason grading system. Am. J. Surg. Pathol. 2012, 36, 838–843. [Google Scholar] [CrossRef] [PubMed]
- Epstein, J.I.; Allsbrook, W.C.; Amin, M.B.; Egevad, L.L. ISUP Grading Committee The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am. J. Surg. Pathol. 2005, 29, 1228–1242. [Google Scholar] [CrossRef]
- Kweldam, C.F.; van Leenders, G.J.; van der Kwast, T. Grading of prostate cancer: A work in progress. Histopathology 2019, 74, 146–160. [Google Scholar] [CrossRef] [PubMed]
- Masoomian, M.; Downes, M.R.; Sweet, J.; Cheung, C.; Evans, A.J.; Fleshner, N.; Maganti, M.; Van der Kwast, T. Concordance of biopsy and prostatectomy diagnosis of intraductal and cribriform carcinoma in a prospectively collected data set. Histopathology 2019, 74, 474–482. [Google Scholar] [CrossRef] [PubMed]
- Humphrey, P.A.; Moch, H.; Cubilla, A.L.; Ulbright, T.M.; Reuter, V.E. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours. Eur. Urol. 2016, 70, 106–119. [Google Scholar] [CrossRef]
- van Leenders, G.J.L.H.; Kweldam, C.F.; Hollemans, E.; Kümmerlin, I.P.; Nieboer, D.; Verhoef, E.I.; Remmers, S.; Incrocci, L.; Bangma, C.H.; van der Kwast, T.H.; et al. Improved Prostate Cancer Biopsy Grading by Incorporation of Invasive Cribriform and Intraductal Carcinoma in the 2014 Grade Groups. Eur. Urol. 2020, 77, 191–198. [Google Scholar] [CrossRef]
- Ma, C.; Downes, M.; Jain, R.; Ientilucci, M.; Fleshner, N.; Perlis, N.; van der Kwast, T. Prevalence of adverse pathology features in grade group 2 prostatectomy specimens with syn- or metachronous metastatic disease. Prostate 2022, 82, 345–351. [Google Scholar] [CrossRef] [PubMed]
- Au, S.; Villamil, C.F.; Alaghehbandan, R.; Wang, G. Prostatic ductal adenocarcinoma with cribriform architecture has worse prognostic features than non-cribriform-type. Ann. Diagn. Pathol. 2019, 39, 59–62. [Google Scholar] [CrossRef]
- de Barros, H.A.; Remmers, S.; Luiting, H.B.; van Leenders, G.J.L.H.; Roobol, M.J.; Bekers, E.M.; Amin, A.; Haynes, A.-M.; Delprado, W.; Stricker, P.D.; et al. Predictive Value of Cribriform and Intraductal Carcinoma for the Nomogram-based Selection of Prostate Cancer Patients for Pelvic Lymph Node Dissection. Urology 2022, 168, 156–164. [Google Scholar] [CrossRef]
- Tonttila, P.P.; Ahtikoski, A.; Kuisma, M.; Pääkkö, E.; Hirvikoski, P.; Vaarala, M.H. Multiparametric MRI prior to radical prostatectomy identifies intraductal and cribriform growth patterns in prostate cancer. BJU Int. 2019, 124, 992–998. [Google Scholar] [CrossRef]
- Chua, M.L.K.; Lo, W.; Pintilie, M.; Murgic, J.; Lalonde, E.; Bhandari, V.; Mahamud, O.; Gopalan, A.; Kweldam, C.F.; van Leenders, G.J.L.H.; et al. A Prostate Cancer “Nimbosus”: Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies. Eur. Urol. 2017, 72, 665–674. [Google Scholar] [CrossRef] [PubMed]
- Elfandy, H.; Armenia, J.; Pederzoli, F.; Pullman, E.; Pertega-Gomes, N.; Schultz, N.; Viswanathan, K.; Vosoughi, A.; Blattner, M.; Stopsack, K.H.; et al. Genetic and Epigenetic Determinants of Aggressiveness in Cribriform Carcinoma of the Prostate. Mol. Cancer Res. 2019, 17, 446–456. [Google Scholar] [CrossRef]
- Shah, R.B.; Shore, K.T.; Yoon, J.; Mendrinos, S.; McKenney, J.K.; Tian, W. PTEN loss in prostatic adenocarcinoma correlates with specific adverse histologic features (intraductal carcinoma, cribriform Gleason pattern 4 and stromogenic carcinoma). Prostate 2019, 79, 1267–1273. [Google Scholar] [CrossRef] [PubMed]
- Greenland, N.Y.; Zhang, L.; Cowan, J.E.; Carroll, P.R.; Stohr, B.A.; Simko, J.P. Correlation of a Commercial Genomic Risk Classifier with Histological Patterns in Prostate Cancer. J. Urol. 2019, 202, 90–95. [Google Scholar] [CrossRef]
- Taylor, A.S.; Morgan, T.M.; Wallington, D.G.; Chinnaiyan, A.M.; Spratt, D.E.; Mehra, R. Correlation between cribriform/intraductal prostatic adenocarcinoma and percent Gleason pattern 4 to a 22-gene genomic classifier. Prostate 2020, 80, 146–152. [Google Scholar] [CrossRef]
- De Marzo, A.M.; Haffner, M.C.; Lotan, T.L.; Yegnasubramanian, S.; Nelson, W.G. Premalignancy in Prostate Cancer: Rethinking What we Know. Cancer Prev. Res. 2016, 9, 648–656. [Google Scholar] [CrossRef] [PubMed]
- Haffner, M.C.; Weier, C.; Xu, M.M.; Vaghasia, A.; Gürel, B.; Gümüşkaya, B.; Esopi, D.M.; Fedor, H.; Tan, H.-L.; Kulac, I.; et al. Molecular evidence that invasive adenocarcinoma can mimic prostatic intraepithelial neoplasia (PIN) and intraductal carcinoma through retrograde glandular colonization. J. Pathol. 2016, 238, 31–41. [Google Scholar] [CrossRef] [PubMed]
- Bostwick, D.G.; Brawer, M.K. Prostatic intra-epithelial neoplasia and early invasion in prostate cancer. Cancer 1987, 59, 788–794. [Google Scholar] [CrossRef] [PubMed]
- Shah, R.B.; Nguyen, J.K.; Przybycin, C.G.; Reynolds, J.P.; Cox, R.; Myles, J.; Klein, E.; McKenney, J.K. Atypical intraductal proliferation detected in prostate needle biopsy is a marker of unsampled intraductal carcinoma and other adverse pathological features: A prospective clinicopathological study of 62 cases with emphasis on pathological outcomes. Histopathology 2019, 75, 346–353. [Google Scholar] [CrossRef] [PubMed]
- Egevad, L.; Delahunt, B.; Iczkowski, K.A.; van der Kwast, T.; van Leenders, G.J.L.H.; Leite, K.R.M.; Pan, C.-C.; Samaratunga, H.; Tsuzuki, T.; Mulliqi, N.; et al. Interobserver reproducibility of cribriform cancer in prostate needle biopsies and validation of International Society of Urological Pathology criteria. Histopathology 2023, 82, 837–845. [Google Scholar] [CrossRef] [PubMed]
- van der Kwast, T.H.; van Leenders, G.J.; Berney, D.M.; Delahunt, B.; Evans, A.J.; Iczkowski, K.A.; McKenney, J.K.; Ro, J.Y.; Samaratunga, H.; Srigley, J.R.; et al. ISUP Consensus Definition of Cribriform Pattern Prostate Cancer. Am. J. Surg. Pathol. 2021, 45, 1118–1126. [Google Scholar] [CrossRef] [PubMed]
- Varma, M.; Delahunt, B.; Egevad, L.; Samaratunga, H.; Kristiansen, G. Intraductal carcinoma of the prostate: A critical re-appraisal. Virchows Arch. 2019, 474, 525–534. [Google Scholar] [CrossRef] [PubMed]
- van Leenders, G.J.L.H.; van der Kwast, T.H.; Grignon, D.J.; Evans, A.J.; Kristiansen, G.; Kweldam, C.F.; Litjens, G.; McKenney, J.K.; Melamed, J.; Mottet, N.; et al. The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma. Am. J. Surg. Pathol. 2020, 44, e87. [Google Scholar] [CrossRef] [PubMed]
- Smith, S.C.; Gandhi, J.S.; Moch, H.; Aron, M.; Compérat, E.; Paner, G.P.; McKenney, J.K.; Amin, M.B. Similarities and Differences in the 2019 ISUP and GUPS Recommendations on Prostate Cancer Grading: A Guide for Practicing Pathologists. Adv. Anat. Pathol. 2021, 28, 1–7. [Google Scholar] [CrossRef]
- Cole, A.I.; Morgan, T.M.; Spratt, D.E.; Palapattu, G.S.; He, C.; Tomlins, S.A.; Weizer, A.Z.; Feng, F.Y.; Wu, A.; Siddiqui, J.; et al. Prognostic Value of Percent Gleason Grade 4 at Prostate Biopsy in Predicting Prostatectomy Pathology and Recurrence. J. Urol. 2016, 196, 405–411. [Google Scholar] [CrossRef]
- Perlis, N.; Sayyid, R.; Evans, A.; Van Der Kwast, T.; Toi, A.; Finelli, A.; Kulkarni, G.; Hamilton, R.; Zlotta, A.R.; Trachtenberg, J.; et al. Limitations in Predicting Organ Confined Prostate Cancer in Patients with Gleason Pattern 4 on Biopsy: Implications for Active Surveillance. J. Urol. 2017, 197, 75–83. [Google Scholar] [CrossRef] [PubMed]
- Sauter, G.; Steurer, S.; Clauditz, T.S.; Krech, T.; Wittmer, C.; Lutz, F.; Lennartz, M.; Janssen, T.; Hakimi, N.; Simon, R.; et al. Clinical Utility of Quantitative Gleason Grading in Prostate Biopsies and Prostatectomy Specimens. Eur. Urol. 2016, 69, 592–598. [Google Scholar] [CrossRef]
- Kweldam, C.F.; Wildhagen, M.F.; Steyerberg, E.W.; Bangma, C.H.; van der Kwast, T.H.; van Leenders, G.J.L.H. Cribriform growth is highly predictive for postoperative metastasis and disease-specific death in Gleason score 7 prostate cancer. Mod. Pathol. 2015, 28, 457–464. [Google Scholar] [CrossRef]
- Kweldam, C.F.; Nieboer, D.; Algaba, F.; Amin, M.B.; Berney, D.M.; Billis, A.; Bostwick, D.G.; Bubendorf, L.; Cheng, L.; Compérat, E.; et al. Gleason grade 4 prostate adenocarcinoma patterns: An interobserver agreement study among genitourinary pathologists. Histopathology 2016, 69, 441–449. [Google Scholar] [CrossRef] [PubMed]
- van der Slot, M.A.; Hollemans, E.; den Bakker, M.A.; Hoedemaeker, R.; Kliffen, M.; Budel, L.M.; Goemaere, N.N.T.; van Leenders, G.J.L.H. Inter-observer variability of cribriform architecture and percent Gleason pattern 4 in prostate cancer: Relation to clinical outcome. Virchows Arch. 2021, 478, 249–256. [Google Scholar] [CrossRef] [PubMed]
- Rijstenberg, L.L.; Hansum, T.; Hollemans, E.; Kweldam, C.F.; Kümmerlin, I.P.; Bangma, C.H.; van der Kwast, T.H.; Roobol, M.J.; van Leenders, G.J.L.H. Intraductal carcinoma has a minimal impact on Grade Group assignment in prostate cancer biopsy and radical prostatectomy specimens. Histopathology 2020, 77, 742–748. [Google Scholar] [CrossRef]
- Downes, M.R.; Liu, K.N.; Yu, Y.; Lajkosz, K.; Kroon, L.J.; Hollemans, E.; Fleshner, N.; Finelli, A.; van Leenders, G.J.L.H.; Iczkowski, K.A.; et al. Addition of Cribriform and Intraductal Carcinoma Presence to Prostate Biopsy Reporting Strengthens Pretreatment Risk Stratification Using CAPRA and NCCN Tools. Clin. Genitourin. Cancer 2024, 22, 47–55. [Google Scholar] [CrossRef]
Lesion Type | p63 | AMACR |
---|---|---|
HG-PIN | + | + |
AIP | + | + weak/on surface |
IDC-P | + | + |
cPCa | − | + |
Acinar PCa | − | + |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Compérat, E.; Kläger, J.; Rioux-Leclercq, N.; Oszwald, A.; Wasinger, G. Cribriform versus Intraductal: How to Determine the Difference. Cancers 2024, 16, 2002. https://doi.org/10.3390/cancers16112002
Compérat E, Kläger J, Rioux-Leclercq N, Oszwald A, Wasinger G. Cribriform versus Intraductal: How to Determine the Difference. Cancers. 2024; 16(11):2002. https://doi.org/10.3390/cancers16112002
Chicago/Turabian StyleCompérat, Eva, Johannes Kläger, Nathalie Rioux-Leclercq, André Oszwald, and Gabriel Wasinger. 2024. "Cribriform versus Intraductal: How to Determine the Difference" Cancers 16, no. 11: 2002. https://doi.org/10.3390/cancers16112002